Exploració per autor "Campbell, Michael J."
Ara es mostren els items 1-5 de 5
-
A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty
Cortés Martínez, Jordi; González Alastrué, José Antonio; Campbell, Michael J.; Cobo Valeri, Erik (2014-10-01)
Article
Accés obertObjectives: To evaluate the empirical concordance between the hazard ratio (HR) and the median ratio (MR) in survival cancer studies. Study Design and Setting: We selected all cancer survival articles from the New England ... -
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
Eldridge, Sandra; Chan, Claire L; Campbell, Michael J.; Bond, Christine M.; Hopewell, Sally; Thabane, Lethana; Lancaster, Gilian A.; Cobo Valeri, Erik (2016-10-24)
Article
Accés oberton behalf of the PAFS consensus group authors (listed alphabetically): Doug Altman (address 1), Frank Bretz (2), Marion Campbell (3), Erik Cobo (4), Peter Craig (5), Peter Davidson (6), Trish Groves (7), Freedom Gumedze ... -
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
Eldridge, Sandra; Chan, Claire L; Campbell, Michael J.; Bond, Christine M.; Hopewell, Sally; Thabane, Lethana; Lancaster, Gilian A.; Cobo Valeri, Erik (Springer, 2016-10-21)
Article
Accés obertThe Consolidated Standards of Reporting Trials (CONSORT) statement is a guideline designed to improve the transparency and quality of the reporting of randomised controlled trials (RCTs). In this article we present an ... -
Does evidence support the high expectations placed in precision medicine? A bibliographic review
Cortés Martínez, Jordi; González Alastrué, José Antonio; Medina, María Nuncia; Vogler, Markus; Vilaró Pacheco, Marta; Elmore, Matthew; Senn, Stephen John; Campbell, Michael J.; Cobo Valeri, Erik (2018-01-09)
Article
Accés obertBackground: Precision medicine is the Holy Grail of interventions that aretailored to a patient’s individual characteristics. However, the conventional design of randomized trials assumes that each individual benefits ... -
Germline genetic contribution to the immune landscape of cancer
Sayaman, Rosalyn W.; Saad, Mohamad; Thorsson, Vésteinn; Hu, Donglei; Hendrickx, Wouter; Roelands, Jessica; Porta Pardo, Eduard; Mokrab, Younes; Farshidfar, Farshad; Kirchhoff, Tomas; Sweis, Randy F.; Bathe, Oliver F.; Heimann, Carolina; Campbell, Michael J.; Stretch, Cynthia; Huntsman, Scott; Graff, Rebecca E.; Syed, Najeeb; Radvanyi, Laszlo; Shelley, Simon; Wolf, Denise; Marincola, Francesco M.; Ceccarelli, Michele; Galon, Jérôme; Ziv, Elad; Bedognetti, Davide (Elsevier, 2021-02)
Article
Accés obertUnderstanding the contribution of the host’s genetic background to cancer immunity may lead to improved stratification for immunotherapy and to the identification of novel therapeutic targets. We investigated the effect ...